
Lupin shares gain ahead of US drug launch that can fetch $200 million in FY26
With this launch, Lupin’s FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to Lupin’s FY26 earnings.

With this launch, Lupin’s FY26 revenue opportunity is estimated at $150–200 million. gTolvaptan could contribute over 25% to Lupin’s FY26 earnings.

Vetri Subramaniam, CIO of UTI Asset Management Company, said he remains constructive but selective on the power sector, noting that rising demand and the growing…

Caplin Point Share Price | Phytonadione injectable emulsion, which mimics the naturally-occurring vitamin K, is used to treat coagulation disorders resulting from deficiencies or interference…

Aurobindo Pharma rose nearly 3% after its subsidiary, Eugia Pharma, got the USFDA approval to make and market Dasatinib Tablets, a leukaemia drug with a…

According to a Bloomberg report, the government is considering cutting import duties on high-end motorcycles in the 705 cc and above category to zero.

Management highlighted that secondary sales for AC and fans have been weak in March and April due to the delayed summer. The management plans to…

As part of the tie-up, Muthoot FinCorp has also invested in BankBazaar’s ongoing Series D2 funding round.

Record date for the purpose of determining the members eligible to receive the dividend for the financial year ended March 31, 2025, has been fixed…

Rahul Chadha, Founder & CIO of Shikhara Investment, said that in a world marked by de-globalisation and policy uncertainty, gold serves as a good hedge,…

In September last year, Suzlon Energy had received its largest wind energy order of 1,166 MW from NTPC Green Energy.